Atopic Dermatitis Patient Pool Analysis, Market Size and Market Forecast APAC - 2036

Atopic Dermatitis Insights and Trends

• Atopic dermatitis, often referred to as eczema, is a chronic (long-lasting) disease that causes inflammation, redness, and irritation of the skin. It is a common condition that usually begins in childhood; however, anyone can get the disease at any age.
• Atopic dermatitis prevalence across Asia-Pacific countries has shown a rising trend over recent decades, particularly in urbanized and industrialized regions, suggesting environmental and lifestyle influences on disease burden.
• Secondary findings indicated that the majority of Atopic dermatitis cases were classified as mild to moderate in severity across all age groups.
• Accurate and timely diagnosis of Atopic dermatitis remains critically important; however, approximately ~25% of cases are either undiagnosed or misdiagnosed, with significant delays in diagnosis being strongly associated with disease progression and burden.
• Currently, the treatment landscape for Atopic dermatitis includes topical therapies such as emollients, topical corticosteroids (TCS), and topical calcineurin inhibitors (TCIs), along with systemic treatment options including immunosuppressants, systemic corticosteroids, and phototherapy. In moderate-to-severe cases, particularly those that are refractory to topical therapies or involve extensive body surface area, systemic therapies are often required.
• The approval and expanding availability of biologics and targeted therapies across APAC markets, particularly agents such as Dupilumab, have significantly transformed the treatment landscape for Atopic dermatitis. While the region had historically relied on topical therapies, systemic corticosteroids, and immunosuppressants, there has been a growing shift toward targeted treatments for moderate-to-severe disease, contributing to improved long-term disease management and broader therapeutic opportunities.
• The approved therapies for moderate-to-severe atopic dermatitis across APAC markets include upadacitinib (RINVOQ), abrocitinib (CIBINQO), tralokinumab (ADBRY/ADTRALZA), nemolizumab (MITCHGA), difamilast (MOIZERTO), and delgocitinib ointment (CORECTIM), with availability varying by country. Several therapies, such as MOIZERTO and CORECTIM, were first introduced in Japan, reflecting the region's role in advancing dermatology innovation. Newer biologics such as lebrikizumab (EBGLYSS) are also expanding into selected APAC markets. However, adoption remains heterogeneous due to differences in regulatory approvals, reimbursement policies, and market access across the region.

DelveInsight's 'Atopic Dermatitis - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of Atopic Dermatitis, historical and forecasted epidemiology, as well as the Atopic Dermatitis market trends in the APAC region (India, China, Japan, South Korea, Taiwan, and Australia).

The Atopic Dermatitis market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates Atopic Dermatitis patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in Atopic Dermatitis and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Atopic Dermatitis Market

Rising Atopic Dermatitis Burden across APAC

The prevalence of atopic dermatitis continues to increase across the APAC region, particularly in rapidly urbanizing and industrializing countries. Rising environmental exposures, air pollution, lifestyle changes, and increasing disease awareness have contributed to a growing patient population across both pediatric and adult groups. The disease burden remains particularly significant in East Asian markets such as Japan, South Korea, and China, creating sustained demand for more effective long-term treatment options and supporting market expansion.

Expanding Therapeutic Opportunities in Atopic Dermatitis

The increasing adoption of targeted biologics and JAK inhibitors across APAC has significantly reshaped treatment approaches for moderate-to-severe atopic dermatitis. Therapies such as DUPIXENT, RINVOQ, CIBINQO, OLUMIANT, and emerging IL-targeted therapies are expanding treatment options beyond traditional topical agents and systemic immunosuppressants. Improved reimbursement frameworks, increasing physician awareness, and broader regulatory approvals across several APAC countries are expected to further improve patient access and support market growth.

Emerging Competitive Landscape in APAC

The APAC atopic dermatitis market is becoming increasingly competitive with a growing pipeline of biologics, oral therapies, and novel immunomodulators. Emerging therapies, including Rocatinlimab, Amlitelimab, Orismilast, Ucenprubart, Bempikibart, and other investigational agents, are advancing clinical development and may further diversify treatment paradigms.

Atopic Dermatitis Understanding and Treatment Algorithm

Atopic Dermatitis Overview

Atopic dermatitis, also called eczema, is a chronic condition and the most common type of skin inflammation that usually starts in early childhood but can occur at any age and can be recurrent or persistent throughout life. In 'dermatitis,' 'derm' means 'skin,' and 'itis' means 'inflammation.' Thus, dermatitis is a skin inflammation characterized by itchiness, redness, and a rash caused by genetics, an overactive immune system, infections, allergies, and irritating substances. Half of the patients with moderate-to-severe eczema also have asthma, hay fever (allergic rhinitis), and food allergies; it is the most common chronic skin disease in children.

Atopic Dermatitis Diagnosis

Atopic dermatitis is primarily diagnosed clinically, as no definitive laboratory test is available for confirmation. Diagnosis is based on characteristic clinical features, particularly pruritus, which is considered an essential symptom, along with chronic or relapsing eczematous lesions, typical age-specific distribution patterns (such as facial and extensor involvement in infants and flexural involvement in older children and adults), and a personal or family history of atopy. The diagnostic process also involves excluding other dermatologic or systemic conditions that may present with similar symptoms. Patients commonly present with dry skin, excoriations, papules, and lichenification. The absence of itching should prompt reconsideration of the diagnosis.

Differential diagnosis is important, especially for other scaly inflammatory skin disorders, such as seborrheic dermatitis in infants. In cases where patients fail to respond adequately to treatment, alternative diagnoses, including nutritional, metabolic, or immunologic disorders, should be considered. Although elevated serum IgE levels are frequently observed in patients with atopic dermatitis, they are not diagnostic. Additional investigations, including skin biopsy and microbiological testing, may assist in excluding other dermatologic conditions or identifying secondary infections; however, these tests are not definitive for diagnosing atopic dermatitis.

Atopic Dermatitis Treatment

The primary goals of atopic dermatitis treatment are to reduce inflammation and pruritus, restore and maintain the skin barrier, prevent flares, minimize infections, and improve quality of life and sleep. Management is stepwise and multidisciplinary, centered on pharmacologic and supportive care. Foundational therapy includes regular use of emollients to maintain skin hydration and topical corticosteroids as first-line anti-inflammatory treatment during flares, with topical calcineurin inhibitors (e.g., tacrolimus, pimecrolimus) or phosphodiesterase-4 inhibitors used for sensitive areas or long-term control.

For moderate-to-severe disease or inadequate response to topical therapy, systemic treatments are used, including biologics such as dupilumab and tralokinumab targeting type 2 inflammation, and oral Janus kinase (JAK) inhibitors (e.g., upadacitinib, abrocitinib) for rapid itch and inflammation control, though they require monitoring for safety risks. Adjunctive measures include antihistamines for itch relief (limited benefit), antimicrobial therapy for secondary infections, and phototherapy in appropriate patients.

Atopic Dermatitis Unmet Needs

The section "unmet needs of Atopic Dermatitis" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Disease burden and impact on the QoL (Quality of Life)

2. Need for more effective treatment therapies

3. Lack of personalized and age-specific treatment

4. Lack of diagnostic guidelines for the management of atopic dermatitis and others.....

Comprehensive unmet needs insights into atopic dermatitis and their strategic implications are provided in the full report.

Atopic Dermatitis Epidemiology

Key Findings from Atopic Dermatitis Epidemiological Analysis and Forecast

• A systematic review of East Asian populations reported a rising prevalence of both pediatric and adult atopic dermatitis across Asian countries, particularly in urban populations, indicating a growing disease burden associated with industrialization and lifestyle changes.
• Findings from the International Study of Asthma and Allergies in Childhood (ISAAC) demonstrated marked geographic heterogeneity across APAC, with childhood atopic dermatitis prevalence reported at approximately 1.2% in China, 3.4% in Korea, and 10.5% in Japan, suggesting substantial regional variation.
• Epidemiological studies in Asia indicate that atopic dermatitis prevalence in children ranges widely (<5% to >20%), with prevalence among 6-7-year-old children approaching 10% in several Asia-Pacific populations, emphasizing a considerable pediatric burden.
• Emerging evidence suggests adult-onset atopic dermatitis is increasingly recognized across Asian populations, expanding the patient pool beyond historically pediatric populations and contributing to long-term disease burden.
• A systematic review and meta-analysis evaluating 162 epidemiological studies across Asia identified both genetic and environmental drivers of atopic dermatitis. Family history of atopic disease emerged as a major non-modifiable factor, while maternal smoking and active smoking were among the strongest modifiable risk factors identified.
• Studies evaluating developing Asian countries reported that atopic dermatitis prevalence is increasing rapidly in regions undergoing economic development and industrial transition, further supporting epidemiological shifts across APAC.
• Studies have suggested that children of Asian immigrant populations may demonstrate increased atopic dermatitis risk, highlighting potential interactions between genetic susceptibility and environmental exposures in disease development.

Atopic Dermatitis Drug Chapters & Competitive Analysis

The Atopic Dermatitis drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I-III clinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the atopic dermatitis treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the atopic dermatitis therapeutics market.

Approved Therapies for Atopic Dermatitis

Upadacitinib (RINVOQ): AbbVie

RINVOQ/RINVOQ LQ, a JAK inhibitor from AbbVie, is indicated for adults and pediatric patients aged 12 years and older with refractory moderate-to-severe Atopic dermatitis inadequately controlled with other systemic therapies, including biologics. The company recently announced topline results from the Phase III/IV LEVEL UP studies and plans to present detailed findings at an upcoming medical congress. AbbVie is also advancing lifecycle expansion efforts in Japan through pediatric studies evaluating RINVOQ in children aged 2-11 years. Additionally, long-term data from the Japanese Phase III Rising Up study demonstrated sustained efficacy and a consistent safety profile for RINVOQ through up to 112 weeks, supporting durable skin clearance and itch reduction in patients with atopic dermatitis.

Atopic Dermatitis Pipeline Analysis

Amlitelimab (KY1005): Sanofi

Amlitelimab is a fully human, non-T-cell-depleting monoclonal antibody that targets OX40L, a key regulator of immune responses. Through its novel mechanism of action, amlitelimab is designed to modulate immune overactivation without depleting T cells and is being developed for immune-mediated and inflammatory disorders, including moderate-to-severe Atopic dermatitis.

According to the Q4 2026 presentation, the company planned to release the remaining Phase III data in the second half of 2026 and aimed to complete regulatory submissions within the same period. In January 2026, following the positive results from the COAST 1 study (NCT06130566) reported in September 2025, two additional global Phase III trials-SHORE (NCT06224348) and COAST 2 (NCT06181435)-further demonstrated the potential of Amlitelimab for the treatment of patients aged 12 years and older with moderate-to-severe Atopic dermatitis. Across both studies, amlitelimab was generally well tolerated, with a safety profile consistent with previously reported clinical data.

Atopic Dermatitis Key Players, Market Leaders, and Emerging Companies

• Roche
• Eli Lilly and Company
• Chugai Pharmaceutical
• Galderma
• Maruho
• AbbVie
• Pfizer
• LEO Pharma
• Otsuka Pharmaceutical
• Incyte Corporation
• Torii Pharmaceutical
• Sanofi
• Regeneron Pharmaceuticals, and others

Atopic Dermatitis Drug Updates

• In March 2026, Eli Lilly announced positive Phase III results (ADorable-1 trial) for lebrikizumab in pediatric atopic dermatitis (>=6 months), demonstrating significant improvements in skin clearance and itch, with plans for regulatory submissions for label expansion.
• In January 2026, recent dermatology updates highlighted the continued expansion of novel therapies for atopic dermatitis, including newer topical and biologic agents, reflecting rapid innovation and broader treatment options across age groups.
• In June 2025, new data for DUPIXENT presented at the Revolutionizing Atopic Dermatitis (RAD) Conference demonstrated substantial improvements in disease severity, itch, hyperpigmentation, and dry skin among patients with skin of color, including Asian populations, further supporting broader applicability across diverse patient groups relevant to APAC markets.
• In February 2025, NEMLUVIO received approval in major international markets for moderate-to-severe atopic dermatitis, strengthening momentum for broader expansion across APAC. The therapy, originally discovered by Japanese company Chugai Pharmaceutical, continues to support regional innovation in atopic dermatitis treatment.

Drug Class Insights

Atopic Dermatitis Market Outlook

For most patients with atopic dermatitis across the APAC region, disease management is primarily achieved through emollients and prescription topical therapies. However, patients with moderate-to-severe disease, extensive skin involvement, significant impairment in quality of life (QoL), or inadequate response to optimized topical treatment often require phototherapy or systemic therapies to achieve better disease control and improve long-term outcomes. Treatment practices across APAC continue to evolve with increasing adoption of personalized and severity-based management strategies.

Historically, the APAC treatment landscape relied heavily on topical corticosteroids, topical calcineurin inhibitors (tacrolimus and pimecrolimus), oral antihistamines, phototherapy, and systemic immunosuppressive therapies. While these treatments remain widely used, increasing awareness of long-term safety concerns and treatment limitations has accelerated the transition toward targeted therapies. Topical PDE-4 inhibitors, including regionally developed products such as difamilast (MOIZERTO), have also expanded topical treatment options, particularly in markets such as Japan.

The introduction and expansion of targeted biologics and JAK inhibitors have significantly reshaped the APAC Atopic Dermatitis market. DUPIXENT marked a major advancement and has gained broad adoption across key APAC markets, including Japan, South Korea, China, and Australia. Additional therapies, including RINVOQ, CIBINQO, ADTRALZA, OLUMIANT, MITCHGA, and MOIZERTO, continue expanding treatment choices for moderate-to-severe disease.

RINVOQ has gained considerable traction in the APAC market due to its rapid itch reduction and strong efficacy profile demonstrated across clinical studies. Growing physician familiarity with oral JAK inhibitors, along with increasing pediatric approvals and expanded indications, is supporting broader uptake despite ongoing safety monitoring considerations.

• The APAC atopic dermatitis market continues to expand due to increasing disease awareness, improving diagnosis rates, and growing adoption of targeted therapies across both pediatric and adult populations.
• The treatment landscape is evolving from conventional immunosuppressive approaches toward precision therapies, with JAK inhibitors and IL-targeted biologics increasingly driving market growth due to favorable efficacy and broader treatment applicability.
• Japan currently represents one of the most advanced APAC markets for atopic dermatitis, supported by early adoption of biologics, innovative topical therapies, and active participation in emerging dermatology drug development.
• Emerging therapies, including amlitelimab, rocatinlimab, orismilast, bempikibart, and lebrikizumab (EBGLYSS), are expected to further intensify competition and diversify future treatment paradigms across APAC.
• Increasing pediatric diagnosis rates, broader reimbursement access, and expansion of targeted therapies into younger age groups are expected to support continued market growth throughout the forecast period.
• In 2025, targeted systemic therapies and biologics are expected to account for an increasing proportion of market value across APAC as treatment patterns continue shifting toward durable and mechanism-driven approaches.

Drug Class/Insights into Leading Emerging and Marketed Therapies in Atopic Dermatitis (2022-2036 Forecast)

The Atopic Dermatitis market comprises targeted biologics, oral small molecules, topical therapies, and emerging immune-modulating approaches, each addressing distinct inflammatory pathways such as type 2 cytokine signaling, JAK-STAT pathways, and skin barrier dysfunction underlying atopic dermatitis.

• Targeted biologics: Dupilumab (DUPIXENT) is a first-in-class IL-4 receptor alpha antagonist that inhibits IL-4 and IL-13 signaling, the central drivers of type 2 inflammation in atopic dermatitis. It has demonstrated strong efficacy and long-term safety across age groups, establishing biologics as the cornerstone of moderate-to-severe atopic dermatitis treatment. Newer biologics such as Tralokinumab (ADTRALZA) and Lebrikizumab further validate IL-13 as a critical therapeutic target and are expanding competition within this class.
• Oral targeted small molecules (JAK inhibitors): Upadacitinib (RINVOQ) and Abrocitinib (CIBINQO) are selective JAK1 inhibitors that provide rapid itch relief and significant skin clearance by modulating multiple cytokine pathways involved in Atopic Dermatitis pathogenesis. These oral agents highlight the growing preference for fast-acting, convenient systemic therapies and are expected to drive significant uptake, particularly among patients seeking alternatives to injectables.
• Emerging therapies targeting novel immune pathways: Pipeline agents such as Nemolizumab, targeting pruritus-specific pathways, and OX40/OX40L inhibitors (e.g., rocatinlimab) are advancing the next wave of Atopic Dermatitis therapies. These agents aim to improve itch control and disease modification, addressing unmet needs in patients with inadequate response to current biologics.

Biologics and JAK inhibitors together define the core innovation landscape in atopic dermatitis, with biologics firmly established as first-line systemic therapies and oral small molecules driving future market expansion through convenience, rapid efficacy, and broader patient applicability during the 2022-2036 forecast period.

Atopic Dermatitis Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the Atopic Dermatitis market's uptake by drugs, patient uptake by therapy, and sales of each drug.

The uptake of therapies in atopic dermatitis across the APAC region is expected to vary across targeted biologics, oral small-molecule inhibitors, and topical agents. Established and expanding targeted therapies such as dupilumab (DUPIXENT), tralokinumab (ADTRALZA), and upadacitinib (RINVOQ) are expected to demonstrate strong and sustained uptake, while lebrikizumab (EBGLYSS) is anticipated to show progressive uptake in selected APAC markets as regulatory expansion continues. Their adoption is supported by targeted mechanisms of action, strong efficacy in moderate-to-severe atopic dermatitis, and increasing physician confidence in biologic and JAK inhibitor use. Uptake is further driven by the limitations of conventional topical corticosteroids and systemic immunosuppressants in achieving durable disease control, along with increasing demand for therapies that provide rapid itch relief and sustained skin clearance.

In comparison, other next-generation therapies such as abrocitinib (CIBINQO) and baricitinib (OLUMIANT) are expected to demonstrate gradual but steady uptake as long-term safety data mature and treatment positioning becomes more clearly defined across APAC practice settings. Additionally, nemolizumab (MITCHGA) and emerging OX40-pathway inhibitors, including investigational therapies such as amlitelimab and rocatinlimab, are projected to gain traction over the forecast period, particularly among patients with persistent pruritus or inadequate response to existing biologics, further diversifying the APAC atopic dermatitis treatment landscape.

Atopic Dermatitis Therapies Price Scenario & Trends

Pricing and analogue assessment of atopic dermatitis therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, the closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

• Pricing of Atopic Dermatitis Approved Drugs

The cost assumptions for DUPIXENT in Japan were based on the recommended dosing regimen, which includes an initial 600 mg dose followed by 300 mg every two weeks for adults, and weight-based dosing every four weeks for pediatric patients aged 6 months to 5 years. Based on these dosing schedules, the estimated annual therapy cost was approximately USD 21,104.

Further details are provided in the final report....

Industry Experts and Physician Views for Atopic Dermatitis

To keep up with atopic dermatitis market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the atopic dermatitis emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in atopic dermatitis, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 10+ key opinion leaders (KOLs) across the APAC region to gather expert insights, with detailed interviews conducted with 6+ KOLs across major Asia-Pacific markets. Leading academic and clinical centers such as the National University of Singapore, the University of Tokyo, Seoul National University, and other prominent dermatology institutions across APAC were engaged. Their perspectives helped validate current and emerging atopic dermatitis therapies, identify unmet medical needs, provide regional epidemiological insights, and support strategic decision-making related to market access, treatment adoption, and pipeline prioritization across the APAC atopic dermatitis landscape.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of Atopic Dermatitis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are mainly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of Atopic Dermatitis, explaining its causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the Atopic Dermatitis market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the APAC drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the APAC Atopic Dermatitis market.

Report Insights

• Atopic Dermatitis Patient Population Forecast
• Atopic Dermatitis Therapeutics Market Size
• Atopic Dermatitis Pipeline Analysis
• Atopic Dermatitis Market Size and Trends
• Atopic Dermatitis Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-enabled Market Research Report
• 11-year forecast
• Atopic Dermatitis Market Outlook (Asia-Pacific)
• Patient Burden Trends (by geography)
• Atopic Dermatitis Treatment Addressable Market (TAM)
• Atopic Dermatitis Competitive Landscape
• Atopic Dermatitis Major Companies Insights
• Atopic Dermatitis Price Trends and Analogue Assessment
• Atopic Dermatitis Therapies Drug Adoption/Uptake
• Atopic Dermatitis Therapies Peak Patient Share Analysis

Report Assessment

• Atopic Dermatitis Current Treatment Practices
• Atopic Dermatitis Unmet Needs
• Atopic Dermatitis Clinical Development Analysis
• Atopic Dermatitis Emerging Drugs Product Profiles
• Atopic Dermatitis Market Attractiveness
• Atopic Dermatitis Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

Market Insights

• What was the Atopic Dermatitis market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of Atopic Dermatitis?
• What are the disease risks, burdens, and unmet needs of Atopic Dermatitis? What will be the growth opportunities across the APAC countries concerning the patient population with Atopic Dermatitis?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of Atopic Dermatitis? What are the current guidelines for treating atopic dermatitis in China, South Korea, Australia, India, Singapore, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Atopic Dermatitis market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying APAC geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis, ranking of class-wise potential current, and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights into the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.